These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 23426441)

  • 1. Prognostic value of cancer stem cells, epithelial-mesenchymal transition and circulating tumor cells in lung cancer.
    Pirozzi G; Tirino V; Camerlingo R; La Rocca A; Martucci N; Scognamiglio G; Franco R; Cantile M; Normanno N; Rocco G
    Oncol Rep; 2013 May; 29(5):1763-8. PubMed ID: 23426441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer.
    Giordano A; Gao H; Anfossi S; Cohen E; Mego M; Lee BN; Tin S; De Laurentiis M; Parker CA; Alvarez RH; Valero V; Ueno NT; De Placido S; Mani SA; Esteva FJ; Cristofanilli M; Reuben JM
    Mol Cancer Ther; 2012 Nov; 11(11):2526-34. PubMed ID: 22973057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct expression of cytokeratin, N-cadherin and CD133 in circulating tumor cells of metastatic breast cancer patients.
    Bock C; Rack B; Huober J; Andergassen U; Jeschke U; Doisneau-Sixou S
    Future Oncol; 2014 Aug; 10(10):1751-65. PubMed ID: 25303055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of CD133 expression in the carcinogenesis and prognosis of patients with lung cancer.
    Le H; Zeng F; Xu L; Liu X; Huang Y
    Mol Med Rep; 2013 Nov; 8(5):1511-8. PubMed ID: 24008862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activated leukocyte cell adhesion molecule (CD166): an "inert" cancer stem cell marker for non-small cell lung cancer?
    Tachezy M; Zander H; Wolters-Eisfeld G; Müller J; Wicklein D; Gebauer F; Izbicki JR; Bockhorn M
    Stem Cells; 2014 Jun; 32(6):1429-36. PubMed ID: 24501004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating tumor and cancer stem cells in hepatitis C virus-associated liver disease.
    Bahnassy AA; Zekri AR; El-Bastawisy A; Fawzy A; Shetta M; Hussein N; Omran D; Ahmed AA; El-Labbody SS
    World J Gastroenterol; 2014 Dec; 20(48):18240-8. PubMed ID: 25561791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CXCR4 is involved in CD133-induced EMT in non-small cell lung cancer.
    Tu Z; Xie S; Xiong M; Liu Y; Yang X; Tembo KM; Huang J; Hu W; Huang X; Pan S; Liu P; Altaf E; Kang G; Xiong J; Zhang Q
    Int J Oncol; 2017 Feb; 50(2):505-514. PubMed ID: 28000861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer.
    Pailler E; Adam J; Barthélémy A; Oulhen M; Auger N; Valent A; Borget I; Planchard D; Taylor M; André F; Soria JC; Vielh P; Besse B; Farace F
    J Clin Oncol; 2013 Jun; 31(18):2273-81. PubMed ID: 23669222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches.
    Krebs MG; Hou JM; Sloane R; Lancashire L; Priest L; Nonaka D; Ward TH; Backen A; Clack G; Hughes A; Ranson M; Blackhall FH; Dive C
    J Thorac Oncol; 2012 Feb; 7(2):306-15. PubMed ID: 22173704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer Stem Cells, Epithelial to Mesenchymal Markers, and Circulating Tumor Cells in Small Cell Lung Cancer.
    Pore M; Meijer C; de Bock GH; Boersma-van Ek W; Terstappen LW; Groen HJ; Timens W; Kruyt FA; Hiltermann TJ
    Clin Lung Cancer; 2016 Nov; 17(6):535-542. PubMed ID: 27363902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating Tumor Cells Enriched by the Depletion of Leukocytes with Bi-Antibodies in Non-Small Cell Lung Cancer: Potential Clinical Application.
    Yin J; Wang Y; Yin H; Chen W; Jin G; Ma H; Dai J; Chen J; Jiang Y; Wang H; Liu Z; Hu Z; Shen H
    PLoS One; 2015; 10(8):e0137076. PubMed ID: 26317979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular detection and prognostic value of epithelial markers mRNA expression in peripheral blood of advanced non-small cell lung cancer patients.
    Arrieta O; Pineda B; Muñiz-Hernández S; Flores D; Ordóñez G; Borbolla-Escoboza JR; Orta D
    Cancer Biomark; 2014; 14(4):215-23. PubMed ID: 24934364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR‑181b‑5p mediates TGF‑β1-induced epithelial-to-mesenchymal transition in non-small cell lung cancer stem-like cells derived from lung adenocarcinoma A549 cells.
    Li X; Han J; Zhu H; Peng L; Chen Z
    Int J Oncol; 2017 Jul; 51(1):158-168. PubMed ID: 28534939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of periostin isoform pattern in non-small cell lung cancer.
    Morra L; Rechsteiner M; Casagrande S; von Teichman A; Schraml P; Moch H; Soltermann A
    Lung Cancer; 2012 May; 76(2):183-90. PubMed ID: 22079858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential Expression of Cancer Stem Cell Markers ALDH1 and CD133 in Various Lung Cancer Subtypes.
    Roudi R; Korourian A; Shariftabrizi A; Madjd Z
    Cancer Invest; 2015; 33(7):294-302. PubMed ID: 26046383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TTF-1 mRNA-positive circulating tumor cells in the peripheral blood predict poor prognosis in surgically resected non-small cell lung cancer patients.
    Yoon SO; Kim YT; Jung KC; Jeon YK; Kim BH; Kim CW
    Lung Cancer; 2011 Feb; 71(2):209-16. PubMed ID: 20471712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Favorable prognosis of operable non-small cell lung cancer (NSCLC) patients harboring an increased expression of tumor endothelial markers (TEMs).
    Pircher A; Fiegl M; Untergasser G; Heidegger I; Medinger M; Kern J; Hilbe W
    Lung Cancer; 2013 Aug; 81(2):252-8. PubMed ID: 23664449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of putative circulating cancer stem cells in patients undergoing hepatic resection for colorectal liver metastasis.
    Pilati P; Mocellin S; Bertazza L; Galdi F; Briarava M; Mammano E; Tessari E; Zavagno G; Nitti D
    Ann Surg Oncol; 2012 Feb; 19(2):402-8. PubMed ID: 22071867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Mesenchymal State Predicts Poor Disease-Free Survival in Resectable Non-Small Cell Lung Cancer.
    Mehta K; Moravcikova E; McFall D; Luketich JD; Pennathur A; Donnenberg AD; Donnenberg VS
    Ann Thorac Surg; 2017 Jul; 104(1):321-328. PubMed ID: 28499650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TGF-β1 exposure induces epithelial to mesenchymal transition both in CSCs and non-CSCs of the A549 cell line, leading to an increase of migration ability in the CD133+ A549 cell fraction.
    Tirino V; Camerlingo R; Bifulco K; Irollo E; Montella R; Paino F; Sessa G; Carriero MV; Normanno N; Rocco G; Pirozzi G
    Cell Death Dis; 2013 May; 4(5):e620. PubMed ID: 23640462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.